Related Experiment Video

Updated: Mar 29, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.4K

[EFFECTIVENESS OF FIXED COMBINATION OF PERINDOPRILARGININE AND AMLODIPINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION

T E Kuznetsova, N Yu Borovkova

    Klinicheskaia Meditsina
    |November 25, 2015
    PubMed

    Insights

    The fixed combination of perindopril arginine and amlodipine besylate effectively treated arterial hypertension in patients with heart failure and kidney disease. This therapy significantly improved blood pressure, clinical symptoms, and physical activity tolerance.

    Area of Science:

    • Cardiology
    • Nephrology
    • Pharmacology

    Context:

    • Arterial hypertension (AH) and chronic cardiac insufficiency (CCI) often coexist with chronic kidney disease (CKD).
    • Managing these complex comorbidities requires effective therapeutic strategies.
    • Assessing the impact of combination therapy on renal function is crucial.

    Purpose:

    • To evaluate the effectiveness of a fixed-dose combination of perindopril arginine and amlodipine besylate.
    • To assess treatment outcomes in patients with essential AH, CCI, and signs of CKD.
    • To monitor changes in blood pressure, clinical status, and renal function markers.

    Summary:

    • A study included 118 patients with essential AH and CCI; 53 with signs of CKD were treated with perindopril arginine/amlodipine besylate (5/5, 5/10, or 10/10 mg).
    • After two months, 82.6% achieved target blood pressure. Significant reductions in systolic and diastolic BP were observed.
    • Clinical conditions improved, physical activity tolerance increased, and markers of renal function (cystatin C, GFR) showed positive changes.

    Impact:

    • The fixed combination therapy demonstrated a high therapeutic effect in managing complex cardiovascular and renal conditions.
    • This treatment strategy offers a viable option for patients with combined arterial hypertension, chronic cardiac insufficiency, and chronic kidney disease.
    • The findings support the use of perindopril arginine and amlodipine besylate in improving both hemodynamic and renal parameters.
    Abstract

    More Related Videos

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

    Published on: October 26, 2020

    5.8K
    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension04:37

    Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

    Published on: June 6, 2025

    860

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.4K
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    520
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    1.1K
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    1.8K
    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    2.8K
    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
    3.0K